Skip to content
OpenCapital
Get started

Pfizer PFE Prevnar Family — Revenues:

Other product segments

Eliquis
$2.17B+12.6%
Vyndaqel family
$1.6B+7.8%
Ibrance
$1.01B+3.2%
All Other Hospital and Biosimilars
$953M—
All other Primary Care
$654M+7.4%
Padcev
$591M+38.7%
All other Specialty Care
$579M+19.1%
Xtandi
$444M-3.1%
Oncology Biosimilars
$409M+54.9%
Royalty
$396M+28.6%
All other Oncology
$376M-0.3%
Nurtec ODT/Vydura
$353M+42.3%
Lorbrena
$305M+37.4%
Pfizer CentreOne
$289M+5.9%
Comirnaty
$232M-58.9%
Paxlovid
$219M-69.9%
Inlyta
$214M-2.3%
Sulperazon (Outside the U.S. and Canada)
$199M+21.3%
Adcetris
$190M-12.8%
Inflectra
$182M—
Abrysvo
$180M+37.4%
Xeljanz
$180M+40.6%
Braftovi/Mektovi
$174M+27.9%
Zavicefta (Outside the U.S. and Canada)
$150M+11.1%
Enbrel (Outside the U.S. and Canada)
$138M-1.4%
Bosulif
$129M-14.6%
Octagam
$122M—
Tukysa
$122M+19.6%
Zithromax
$112M-29.1%
Orgovyx
$109M—
Genotropin
$93M—
FSME-IMMUN/TicoVac
$81M—
Elrexfio
$80M+33.3%
Cibinqo
$76M+31.0%
Talzenna
$50M+25.0%
Tivdak
$33M0.0%

Similar metrics at other companies

Novavax logo
NVAXProduct sales — Total Revenue
$42.2M-93.2%
Zoetis logo
ZTSVaccines — Revenue
$519M+18.2%
BillionToOne, Inc. logo
BLLNPrenatal — Revenue
$96.53M+72.1%
Myriad Genetics logo
MYGNPrenatal Health — Revenue
$41.9M-15.0%
Myriad Genetics logo
MYGNPrenatal — Revenue
$44.9M0.0%
RFL
RFLProduct Revenue — Revenue
$89K-63.4%

Other financials

Income statement

See full
Revenue$14.5B+5.4%
Gross profit$10.9B+0.3%
Net income$2.7B-9.4%
EPS (diluted)$0.47-9.6%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+4.9%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$138.21B-3.7%
Enterprise value$200.88B-1.3%
P/E11.4×—
P/S2.2×-0.1×

Profitability

See full
Gross margin73.5%+1.2pp
Net margin15.7%—
FCF margin18%+8.8pp

Returns & leverage

See full
Return on equity10.6%—
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's prevnar family — revenues:.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pfizer's prevnar family — revenues:?
Pfizer (PFE) reported prevnar family — revenues: of $1.69B in Q1 2026.
How has Pfizer's prevnar family — revenues: changed year-over-year?
Pfizer's prevnar family — revenues: increased by 1.8% year-over-year, from $1.66B to $1.69B.
What is the long-term trend for Pfizer's prevnar family — revenues:?
Over 4 years (2021 to 2025), Pfizer's prevnar family — revenues: has grown at a 5.3% compound annual growth rate (CAGR), from $5.27B to $6.49B.
What does prevnar family — revenues: mean?
This metric represents the total gross sales generated by a specific portfolio of pneumococcal conjugate vaccines within a pharmaceutical company's product lineup. It serves as a key indicator of the commercial performance and market penetration of the firm's vaccine franchise in both pediatric and adult immunization markets. Tracking these revenues helps investors assess the stability and growth trajectory of a core therapeutic area that often benefits from long-term government contracts and public health mandates.